Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Lung cancer highlights.

T J Lynch1

  • 1Massachusetts General Hospital Cancer Center, Boston, Massachusetts 02114-2617, USA. lynch.thomas@mbh.harvard.edu

The Oncologist
|August 31, 2000
PubMed
Summary
This summary is machine-generated.

Despite comparing four platinum-based doublets in advanced non-small cell lung cancer (NSCLC), ECOG 1594 showed no survival improvements. However, novel agents targeting EGFR and VEGF show promise for future NSCLC treatment.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-up.

Annals of oncology : official journal of the European Society for Medical Oncology·2018
Same author

Mutation profiles in early-stage lung squamous cell carcinoma with clinical follow-up and correlation with markers of immune function.

Annals of oncology : official journal of the European Society for Medical Oncology·2017
Same author

Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-up.

Annals of oncology : official journal of the European Society for Medical Oncology·2016
Same author

Butyrylcholinesterase: an enzyme antidote for cocaine intoxication.

Addiction biology·2016
Same author

Clinical outcomes in elderly patients with advanced non-small cell lung cancer: results from ARIES, a bevacizumab observational cohort study.

Clinical oncology (Royal College of Radiologists (Great Britain))·2015
Same author

Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2012
Same journal

Prevalence, treatment and survival of Malignant Peripheral Nerve Sheath Tumor in the Danish neurofibromatosis type 1 population.

The oncologist·2026
Same journal

Molecular Tumor Board-Guided Osimertinib Therapy in EGFR L858R/Q701L-Mutant Lung Adenocarcinoma Supported by Functional Validation.

The oncologist·2026
Same journal

Phase 2 Dose Expansion Trial of OBI-3424, a DNA-Alkylating Prodrug, in Patients with Advanced Solid Tumors Expressing AKR1C3.

The oncologist·2026
Same journal

Divergent Biology and Outcomes of Somatic Transformations in Germ Cell Tumors.

The oncologist·2026
Same journal

Modernizing Disease Assessment in Prostate Cancer Trials: The Prostate Cancer Working Group 4 Framework.

The oncologist·2026
Same journal

Use of liposomal irinotecan with 5-FU and oxaliplatin (NALIRIFOX) in neoadjuvant pancreatic adenocarcinoma: NEO-Nal-IRI trial.

The oncologist·2026
See all related articles

Area of Science:

  • Medical Oncology
  • Clinical Trials
  • Cancer Research

Background:

  • Assessing treatment progress for advanced non-small cell lung cancer (NSCLC) over 15 years.
  • Evaluating the Eastern Cooperative Oncology Group (ECOG) 1594 trial comparing four platinum-based doublets in metastatic lung cancer.
  • Dr. Francis Shepherd's commentary on the "snail's pace" of progress in metastatic lung cancer treatment.

Framework:

  • ECOG 1594: A large randomized trial comparing four platinum-based doublet regimens.
  • Primary endpoint: Survival. Secondary endpoint: Response and time to progression.
  • Analysis of survival, response, and time to progression across treatment arms.

Implementation:

  • No significant differences in survival or response were observed between the four regimens.

Related Experiment Videos

  • The cisplatin/gemcitabine arm demonstrated a superior time to progression.
  • Results presented at the 36th Annual Meeting of the American Society of Clinical Oncology (ASCO).

    • Implications:

    • Limited progress in standard chemotherapy for advanced NSCLC based on ECOG 1594.
    • Emerging novel agents, including Iressa (anti-epidermal growth factor receptor tyrosine kinase) and anti-vascular endothelial growth factor monoclonal antibodies, show potential.
    • Cisplatin/irinotecan combination demonstrated superiority over cisplatin/etoposide in small-cell lung cancer, suggesting new therapeutic avenues.